All In Biotech

NDA 016964 · Hospira

Marcaine Hydrochloride W/ Epinephrine Preservative Free

Bupivacaine Hydrochloride, Epinephrine Bitartrate · Injection

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Aug 21, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1972

Oct 3, 1972

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,836

341 Phase 3, 228 recruiting

FAERS reports

4,747

2,732 serious, 318 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF CARDIAC ARREST WITH USE OF MARCAINE IN OBSTETRICAL ANESTHESIA There have been reports of cardiac arrest with difficult resuscitation or death during use of MARCAINE for epidural anesthesia in obstetrical patients. In most cases, this has followed use of the 0.75% (7.5 mg/mL) concentration. Resuscitation has been difficult or impossible despite apparently adequate preparation and appropriate management. Cardiac arrest has occurred after convulsions resulting from systemic toxicity, presumably following unintentional intravascular injection. The 0.75% (7.5 mg/mL) concentration of MARCAINE is not recommended for obstetrical anesthesia and should be reserved for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary [see Warnings and Precautions (5.1) ] . WARNING: RISK OF CARDIAC ARREST WITH USE OF MARCAINE IN OBSTETRICAL ANESTHESIA...

What it is approved for

From the label in effect Oct 23, 2026.

MARCAINE / MARCAINE WITH EPINEPHRINE is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Specific concentrations and presentations of MARCAINE / MARCAINE WITH EPINEPHRINE are recommended for each type of block indicated to produce local or regional anesthesia or analgesia [see Dosage and Administration (2.2) ]. MARCAINE contains bupivacaine, an amide local anesthetic, and MARCAINE WITH EPINEPHRINE is a combination of bupivacaine, an amide local anesthetic, and epinephrine, an alpha and beta-adrenergic agonist. MARCAINE / MARCAINE WITH EPINEPHRINE is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. For each type of block indicated to produce local or regional anesthesia or analgesia, specific concentrations and presentations are recommended. ( 1 , 2.2 ) Limitations of Use Not all blocks are indicated for use with MARCAINE / MARCAINE WITH EPINEPHRINE given clinically significant risks associated with use. ( 1 , 2.2 , 4 , 5.1 , 5.4 , 5.5 , 5.7 , 5.9 ) Limitations of Use Not all blocks are indicated for use with MARCAINE / MARCAINE WITH EPINEPHRINE given clinically significant risks associated with use [see Dosage and Administration (2.2) , Contraindications (4) , Warnings and Precautions (5.1 , 5.4 , 5.5 , 5.7 , 5.9) ] .

Mechanism: Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone. Epinephrine is a vasoconstrictor added to bupivacaine to...

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 3, 1972 Original approval · Type 1 - New Molecular Entity · priority review
10 products under this application
  • MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE · BUPIVACAINE HYDROCHLORIDE 0.25%; EPINEPHRINE BITARTRATE 0.0091MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • MARCAINE HYDROCHLORIDE PRESERVATIVE FREE · BUPIVACAINE HYDROCHLORIDE 0.5% · INJECTABLE, INJECTION · Prescription · TE AP
  • MARCAINE HYDROCHLORIDE · BUPIVACAINE HYDROCHLORIDE 0.25% · INJECTABLE, INJECTION · Prescription · TE AP
  • MARCAINE HYDROCHLORIDE W/ EPINEPHRINE · BUPIVACAINE HYDROCHLORIDE 0.5%; EPINEPHRINE BITARTRATE 0.0091MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • MARCAINE HYDROCHLORIDE · BUPIVACAINE HYDROCHLORIDE 0.5% · INJECTABLE, INJECTION · Prescription · TE AP
  • MARCAINE HYDROCHLORIDE PRESERVATIVE FREE · BUPIVACAINE HYDROCHLORIDE 0.25% · INJECTABLE, INJECTION · Prescription · TE AP
  • MARCAINE HYDROCHLORIDE W/ EPINEPHRINE · BUPIVACAINE HYDROCHLORIDE 0.25%; EPINEPHRINE BITARTRATE 0.0091MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE · BUPIVACAINE HYDROCHLORIDE 0.75%; EPINEPHRINE BITARTRATE 0.0091MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • MARCAINE HYDROCHLORIDE PRESERVATIVE FREE · BUPIVACAINE HYDROCHLORIDE 0.75% · INJECTABLE, INJECTION · Prescription · TE AP
  • MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE · BUPIVACAINE HYDROCHLORIDE 0.5%; EPINEPHRINE BITARTRATE 0.0091MG/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Bupivacaine" as an intervention, any sponsor and status, largest first.

All 2,836 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,603
  • anaesthetic complication278
  • off label use246
  • pain228
  • hypoaesthesia213
  • maternal exposure during pregnancy211
  • hypotension199
  • headache181
  • dyspnoea169
  • dizziness154
  • nausea149
  • condition aggravated144

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200492
200577
200697
200765
200885
2009124
2010104
2011101
201294
201394
2014112
2015191
2016619
2017390
2018241
2019242
2020242
2021200
2022407
2023256
2024331
2025336
2026247

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 9, 2026

    Marcaine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-7535-01).

  • Current · updated Nov 9, 2026

    Marcaine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1530-01).

  • Current · updated Nov 9, 2026

    Marcaine with Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50).

  • Current · updated Nov 9, 2026

    Marcaine with Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10).

  • Current · updated Nov 9, 2026

    Marcaine, Injection, 250 mg/50 mL (NDC 0409-0525-25). Historical NDC: 0409-1610-50

  • Current · updated Nov 9, 2026

    Marcaine, Injection, Marcaine 225 mg/30 mL (7.5 mg/mL) (NDC 0409-2253-01). Historical NDC: 0409-1582-29

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,896 on PubMed

Sponsor: Pfizer · Also marketed as Marcaine Hydrochloride Preservative Free, Marcaine Hydrochloride, Marcaine Hydrochloride W/ Epinephrine

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.